Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of Anemia.

Debenham JS, Madsen-Duggan C, Clements MJ, Walsh TF, Kuethe JT, Reibarkh M, Salowe SP, Sonatore LM, Hajdu R, Milligan JA, Visco DM, Zhou D, Lingham RB, Stickens D, DeMartino JA, Tong X, Wolff M, Pang J, Miller RR, Sherer EC, Hale JJ.

J Med Chem. 2016 Dec 22;59(24):11039-11049. doi: 10.1021/acs.jmedchem.6b01242. Epub 2016 Nov 30.

PMID:
28002958
2.

Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.

Di Salvo J, Nagabukuro H, Wickham LA, Abbadie C, DeMartino JA, Fitzmaurice A, Gichuru L, Kulick A, Donnelly MJ, Jochnowitz N, Hurley AL, Pereira A, Sanfiz A, Veronin G, Villa K, Woods J, Zamlynny B, Zycband E, Salituro GM, Frenkl T, Weber AE, Edmondson SD, Struthers M.

J Pharmacol Exp Ther. 2017 Feb;360(2):346-355. doi: 10.1124/jpet.116.237313. Epub 2016 Dec 13.

PMID:
27965369
3.

NCCN Work Group Report: Emerging Issues in Tissue Allocation.

DeMartino JK.

J Natl Compr Canc Netw. 2016 Mar;14(3):265-71.

PMID:
26957613
4.

Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants.

Hartkamp LM, Fine JS, van Es IE, Tang MW, Smith M, Woods J, Narula S, DeMartino J, Tak PP, Reedquist KA.

Ann Rheum Dis. 2015 Aug;74(8):1603-11. doi: 10.1136/annrheumdis-2013-204143. Epub 2014 Apr 24.

PMID:
24764451
5.

Measuring quality in oncology: challenges and opportunities.

DeMartino JK.

J Natl Compr Canc Netw. 2013 Dec 1;11(12):1482-91. Review.

PMID:
24335683
6.

Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.

Liao C, Hsu J, Kim Y, Hu DQ, Xu D, Zhang J, Pashine A, Menke J, Whittard T, Romero N, Truitt T, Slade M, Lukacs C, Hermann J, Zhou M, Lucas M, Narula S, DeMartino J, Tan SL.

Arthritis Res Ther. 2013 Oct 4;15(5):R146. doi: 10.1186/ar4329.

7.

Evolving policy issues in oncology: revisiting biosimilars and molecular testing.

DeMartino J.

J Natl Compr Canc Netw. 2013 Sep 1;11(9):1174-7. No abstract available.

PMID:
24029129
8.

Biological and structural evaluation of 10R- and 10S-methylthio-DDACTHF reveals a new role for sulfur in inhibition of glycinamide ribonucleotide transformylase.

Connelly S, DeMartino JK, Boger DL, Wilson IA.

Biochemistry. 2013 Jul 30;52(30):5133-44. doi: 10.1021/bi4005182. Epub 2013 Jul 19.

9.

Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis.

Tang X, Peng R, Phillips JE, Deguzman J, Ren Y, Apparsundaram S, Luo Q, Bauer CM, Fuentes ME, DeMartino JA, Tyagi G, Garrido R, Hogaboam CM, Denton CP, Holmes AM, Kitson C, Stevenson CS, Budd DC.

Am J Pathol. 2013 Aug;183(2):470-9. doi: 10.1016/j.ajpath.2013.04.020. Epub 2013 Jun 10.

PMID:
23759512
10.

Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase.

Mina-Osorio P, LaStant J, Keirstead N, Whittard T, Ayala J, Stefanova S, Garrido R, Dimaano N, Hilton H, Giron M, Lau KY, Hang J, Postelnek J, Kim Y, Min S, Patel A, Woods J, Ramanujam M, DeMartino J, Narula S, Xu D.

Arthritis Rheum. 2013 Sep;65(9):2380-91. doi: 10.1002/art.38047.

11.

Development of a pharmacodynamic assay based on PLCγ2 phosphorylation for quantifying spleen tyrosine kinase (SYK)-Bruton's tyrosine kinase (BTK) signaling.

Hsu J, Zhang J, Kitson C, Tan SL, Narula S, DeMartino JA, Liao C.

J Biomol Screen. 2013 Sep;18(8):890-8. doi: 10.1177/1087057113489881. Epub 2013 May 23.

PMID:
23704133
12.

Natural regulatory T cells are resistant to calcium release-activated calcium (CRAC/ORAI) channel inhibition.

Jin S, Chin J, Kitson C, Woods J, Majmudar R, Carvajal V, Allard J, Demartino J, Narula S, Thomas-Karyat DA.

Int Immunol. 2013 Sep;25(9):497-506. doi: 10.1093/intimm/dxt013. Epub 2013 May 10.

PMID:
23667148
13.

Data Needs in Oncology: “Making Sense of The Big Data Soup”

Larsen JK, DeMartino JK.

J Natl Compr Canc Netw. 2013 Apr 1;11(11 Suppl 2):S1-S12. doi: 10.6004/jnccn.2013.0214.

PMID:
31094497
14.

Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives.

Tan SL, Liao C, Lucas MC, Stevenson C, DeMartino JA.

Pharmacol Ther. 2013 May;138(2):294-309. doi: 10.1016/j.pharmthera.2013.02.001. Epub 2013 Feb 7. Review.

PMID:
23396081
15.

Characterization of a novel CRAC inhibitor that potently blocks human T cell activation and effector functions.

Chen G, Panicker S, Lau KY, Apparsundaram S, Patel VA, Chen SL, Soto R, Jung JK, Ravindran P, Okuhara D, Bohnert G, Che Q, Rao PE, Allard JD, Badi L, Bitter HM, Nunn PA, Narula SK, DeMartino JA.

Mol Immunol. 2013 Jul;54(3-4):355-67. doi: 10.1016/j.molimm.2012.12.011. Epub 2013 Jan 26.

PMID:
23357789
16.

Bruton's Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: a potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints.

Hsu J, Gu Y, Tan SL, Narula S, DeMartino JA, Liao C.

Immunol Lett. 2013 Feb;150(1-2):97-104. doi: 10.1016/j.imlet.2012.12.007. Epub 2012 Dec 21.

PMID:
23266841
17.

TL1A/TNFSF15 directly induces proinflammatory cytokines, including TNFα, from CD3+CD161+ T cells to exacerbate gut inflammation.

Jin S, Chin J, Seeber S, Niewoehner J, Weiser B, Beaucamp N, Woods J, Murphy C, Fanning A, Shanahan F, Nally K, Kajekar R, Salas A, Planell N, Lozano J, Panes J, Parmar H, DeMartino J, Narula S, Thomas-Karyat DA.

Mucosal Immunol. 2013 Sep;6(5):886-99. doi: 10.1038/mi.2012.124. Epub 2012 Dec 19.

PMID:
23250276
18.

Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities.

Gray PM, Forrest G, Wisniewski T, Porter G, Freed DC, DeMartino JA, Zaller DM, Guo Z, Leone J, Fu TM, Vora KA.

Cell Immunol. 2012 Jul-Aug;278(1-2):113-9. doi: 10.1016/j.cellimm.2012.07.006. Epub 2012 Aug 4.

PMID:
23121983
19.

BET bromodomain proteins mediate downstream signaling events following growth factor stimulation in human lung fibroblasts and are involved in bleomycin-induced pulmonary fibrosis.

Tang X, Peng R, Ren Y, Apparsundaram S, Deguzman J, Bauer CM, Hoffman AF, Hamilton S, Liang Z, Zeng H, Fuentes ME, Demartino JA, Kitson C, Stevenson CS, Budd DC.

Mol Pharmacol. 2013 Jan;83(1):283-93. doi: 10.1124/mol.112.081661. Epub 2012 Oct 31.

PMID:
23115324
20.

Equity in cancer care: pathways, protocols, and guidelines.

DeMartino JK, Larsen JK.

J Natl Compr Canc Netw. 2012 Oct 1;10 Suppl 1:S1-9.

PMID:
23042831
21.

Quantifying monocyte infiltration in response to intradermal tetanus toxoid injection.

Peng JZ, Gutstein DE, Beck L, Hickey L, Hustad CM, Abbi S, Nirula A, DeMartino J, Rothenberg P, Gottesdiener K, Bloomfield DM, Wagner JA.

Biomark Med. 2012 Aug;6(4):541-51. doi: 10.2217/bmm.12.43.

PMID:
22917155
22.

1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.

Vachal P, Miao S, Pierce JM, Guiadeen D, Colandrea VJ, Wyvratt MJ, Salowe SP, Sonatore LM, Milligan JA, Hajdu R, Gollapudi A, Keohane CA, Lingham RB, Mandala SM, DeMartino JA, Tong X, Wolff M, Steinhuebel D, Kieczykowski GR, Fleitz FJ, Chapman K, Athanasopoulos J, Adam G, Akyuz CD, Jena DK, Lusen JW, Meng J, Stein BD, Xia L, Sherer EC, Hale JJ.

J Med Chem. 2012 Apr 12;55(7):2945-59. doi: 10.1021/jm201542d. Epub 2012 Feb 27.

PMID:
22364528
23.

RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.

Xu D, Kim Y, Postelnek J, Vu MD, Hu DQ, Liao C, Bradshaw M, Hsu J, Zhang J, Pashine A, Srinivasan D, Woods J, Levin A, O'Mahony A, Owens TD, Lou Y, Hill RJ, Narula S, DeMartino J, Fine JS.

J Pharmacol Exp Ther. 2012 Apr;341(1):90-103. doi: 10.1124/jpet.111.187740. Epub 2012 Jan 6.

PMID:
22228807
24.

NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement.

Engstrom PF, Bloom MG, Demetri GD, Febbo PG, Goeckeler W, Ladanyi M, Loy B, Murphy K, Nerenberg M, Papagni P, Robson M, Sweetman RW, Tunis S, Demartino J, Larsen JK; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Dec;9 Suppl 6:S1-16.

PMID:
22203777
25.

Optimization of erythropoietin production with controlled glycosylation-PEGylated erythropoietin produced in glycoengineered Pichia pastoris.

Nett JH, Gomathinayagam S, Hamilton SR, Gong B, Davidson RC, Du M, Hopkins D, Mitchell T, Mallem MR, Nylen A, Shaikh SS, Sharkey N, Barnard GC, Copeland V, Liu L, Evers R, Li Y, Gray PM, Lingham RB, Visco D, Forrest G, DeMartino J, Linden T, Potgieter TI, Wildt S, Stadheim TA, d'Anjou M, Li H, Sethuraman N.

J Biotechnol. 2012 Jan;157(1):198-206. doi: 10.1016/j.jbiotec.2011.11.002. Epub 2011 Nov 9.

PMID:
22100268
26.

NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.

Zelenetz AD, Ahmed I, Braud EL, Cross JD, Davenport-Ennis N, Dickinson BD, Goldberg SE, Gottlieb S, Johnson PE, Lyman GH, Markus R, Matulonis UA, Reinke D, Li EC, DeMartino J, Larsen JK, Hoffman JM.

J Natl Compr Canc Netw. 2011 Sep;9 Suppl 4:S1-22.

PMID:
21976013
27.

Biosimilars: approval and acceptance?

DeMartino JK.

J Natl Compr Canc Netw. 2011 Feb;9 Suppl 3:S6-9. No abstract available.

PMID:
21357668
28.

NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for Stakeholders.

Johnson PE, Dahlman G, Eng K, Garg R, Gottlieb S, Hoffman JM, Howell P, Jahanzeb M, Johnson S, Mackler E, Rubino M, Sarokhan B, Marc Stewart F, Tyler T, Vose JM, Weinstein S, Li EC, Demartino J; NCCN Oncology Risk Evaluation and Mitigation Strategies (REMS) Work Group.

J Natl Compr Canc Netw. 2010 Sep;8 Suppl 7:S7-S27.

PMID:
20947724
29.

Changes to medicare part D: who benefits?

DeMartino JK.

J Natl Compr Canc Netw. 2010 Sep;8 Suppl 7:S4-6. No abstract available.

PMID:
20947723
30.

Managed care & medical oncology: the focus is on value.

Danielson E, Demartino J, Mullen JA.

J Natl Compr Canc Netw. 2010 Sep;8 Suppl 7:S28-37.

PMID:
20947721
32.

Dual targeting of CCR2 and CX3CR1 in an arterial injury model of vascular inflammation.

Jerath MR, Liu P, Struthers M, Demartino JA, Peng R, Peterson LB, Cumiskey AM, Yang L, Rojas M, Patel DD, Fong AM.

Thromb J. 2010 Sep 13;8:14. doi: 10.1186/1477-9560-8-14.

33.

Fused tricyclic pyrrolizinones that exhibit pseudo-irreversible blockade of the NK1 receptor.

Morriello GJ, Chicchi G, Johnson T, Mills SG, Demartino J, Kurtz M, Tsao KL, Zheng S, Tong X, Carlson E, Townson K, Wheeldon A, Boyce S, Collinson N, Rupniak N, Devita RJ.

Bioorg Med Chem Lett. 2010 Oct 1;20(19):5925-32. doi: 10.1016/j.bmcl.2010.07.058. Epub 2010 Jul 19.

PMID:
20729082
34.

Substituted fused bicyclic pyrrolizinones as potent, orally bioavailable hNK1 antagonists.

Morriello GJ, Mills SG, Johnson T, Reibarkh M, Chicchi G, DeMartino J, Kurtz M, Davies P, Tsao KL, Zheng S, Tong X, Carlson E, Townson K, Tattersall FD, Wheeldon A, Boyce S, Collinson N, Rupniak N, Moore S, DeVita RJ.

Bioorg Med Chem Lett. 2010 Mar 15;20(6):2007-12. doi: 10.1016/j.bmcl.2010.01.065. Epub 2010 Jan 20.

PMID:
20153964
35.

Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist.

Wisniewski T, Bayne E, Flanagan J, Shao Q, Wnek R, Matheravidathu S, Fischer P, Forrest MJ, Peterson L, Song X, Yang L, Demartino JA, Struthers M.

J Immunol Methods. 2010 Jan 31;352(1-2):101-10. doi: 10.1016/j.jim.2009.10.010. Epub 2009 Nov 10.

PMID:
19913021
36.

Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by alpha-ketoheterocycle inhibitors revealed from cocrystal structures.

Mileni M, Garfunkle J, DeMartino JK, Cravatt BF, Boger DL, Stevens RC.

J Am Chem Soc. 2009 Aug 5;131(30):10497-506. doi: 10.1021/ja902694n.

37.

Design, synthesis, and structure-activity relationship of novel CCR2 antagonists.

Kothandaraman S, Donnely KL, Butora G, Jiao R, Pasternak A, Morriello GJ, Goble SD, Zhou C, Mills SG, Maccoss M, Vicario PP, Ayala JM, Demartino JA, Struthers M, Cascieri MA, Yang L.

Bioorg Med Chem Lett. 2009 Mar 15;19(6):1830-4. doi: 10.1016/j.bmcl.2008.12.050. Epub 2008 Dec 24.

PMID:
19237282
38.

Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase.

DeMartino JK, Hwang I, Connelly S, Wilson IA, Boger DL.

J Med Chem. 2008 Sep 11;51(17):5441-8. doi: 10.1021/jm800555h. Epub 2008 Aug 8.

39.

Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hydrolase.

DeMartino JK, Garfunkle J, Hochstatter DG, Cravatt BF, Boger DL.

Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6. doi: 10.1016/j.bmcl.2008.06.084. Epub 2008 Jun 28.

40.

Unaltered graft survival and intragraft lymphocytes infiltration in the cardiac allograft of Cxcr3-/- mouse recipients.

Kwun J, Hazinedaroglu SM, Schadde E, Kayaoglu HA, Fechner J, Hu HZ, Roenneburg D, Torrealba J, Shiao L, Hong X, Peng R, Szewczyk JW, Sullivan KA, DeMartino J, Knechtle SJ.

Am J Transplant. 2008 Aug;8(8):1593-603. doi: 10.1111/j.1600-6143.2008.02250.x. Epub 2008 May 12.

41.

Fused bicyclic pyrrolizinones as new scaffolds for human NK1 antagonists.

Morriello GJ, Devita RJ, Mills SG, Young JR, Lin P, Doss G, Chicchi GG, Demartino J, Kurtz MM, Tsao KL, Carlson E, Townson K, Wheeldon A, Boyce S, Collinson N, Rupniak N, Moore S.

Bioorg Med Chem. 2008 Mar 1;16(5):2156-70. doi: 10.1016/j.bmc.2007.11.081. Epub 2007 Dec 5.

PMID:
18248994
42.

Conformational studies of 3-amino-1-alkyl-cyclopentane carboxamide CCR2 antagonists leading to new spirocyclic antagonists.

Pasternak A, Goble SD, Doss GA, Tsou NN, Butora G, Vicario PP, Ayala JM, Struthers M, Demartino JA, Mills SG, Yang L.

Bioorg Med Chem Lett. 2008 Feb 15;18(4):1374-7. doi: 10.1016/j.bmcl.2008.01.016. Epub 2008 Jan 9.

PMID:
18215519
43.

Potent heteroarylpiperidine and carboxyphenylpiperidine 1-alkyl-cyclopentane carboxamide CCR2 antagonists.

Pasternak A, Goble SD, Vicario PP, Di Salvo J, Ayala JM, Struthers M, DeMartino JA, Mills SG, Yang L.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):994-8. doi: 10.1016/j.bmcl.2007.12.029. Epub 2007 Dec 27.

PMID:
18164199
44.
45.

Mice overexpressing chemokine ligand 2 (CCL2) in astrocytes display enhanced nociceptive responses.

Menetski J, Mistry S, Lu M, Mudgett JS, Ransohoff RM, Demartino JA, Macintyre DE, Abbadie C.

Neuroscience. 2007 Nov 9;149(3):706-14. Epub 2007 Aug 14.

PMID:
17870246
46.

CCR5 blockade modulates inflammation and alloimmunity in primates.

Schröder C, Pierson RN 3rd, Nguyen BN, Kawka DW, Peterson LB, Wu G, Zhang T, Springer MS, Siciliano SJ, Iliff S, Ayala JM, Lu M, Mudgett JS, Lyons K, Mills SG, Miller GG, Singer II, Azimzadeh AM, DeMartino JA.

J Immunol. 2007 Aug 15;179(4):2289-99.

47.

Diaryl substituted pyrazoles as potent CCR2 receptor antagonists.

Pinkerton AB, Huang D, Cube RV, Hutchinson JH, Struthers M, Ayala JM, Vicario PP, Patel SR, Wisniewski T, DeMartino JA, Vernier JM.

Bioorg Med Chem Lett. 2007 Feb 1;17(3):807-13. Epub 2006 Oct 25.

PMID:
17088058
48.

Discovery of a potent, nonpolyglutamatable inhibitor of glycinamide ribonucleotide transformylase.

DeMartino JK, Hwang I, Xu L, Wilson IA, Boger DL.

J Med Chem. 2006 May 18;49(10):2998-3002.

49.

Severe disease, unaltered leukocyte migration, and reduced IFN-gamma production in CXCR3-/- mice with experimental autoimmune encephalomyelitis.

Liu L, Huang D, Matsui M, He TT, Hu T, Demartino J, Lu B, Gerard C, Ransohoff RM.

J Immunol. 2006 Apr 1;176(7):4399-409.

50.

Methylxanthine drugs are chitinase inhibitors: investigation of inhibition and binding modes.

Rao FV, Andersen OA, Vora KA, Demartino JA, van Aalten DM.

Chem Biol. 2005 Sep;12(9):973-80.

Supplemental Content

Loading ...
Support Center